The presence of certain biomarkers, such as mutated isocitrate dehydrogenase (IDH), O6-methylguanine DNA methyltransferase (MGMT) promoter hypermethylation, epidermal growth factor receptor amplification, and p53 mutations in GBM offer prognostic and diagnostic potential. The gene discussed is MGMT; the disease is glioblastoma.